Neuland Laboratories Ltd. · NSE:NEULANDLAB
Neuland Laboratories — Q4 FY26 Earnings Presentation
38 slides from Neuland Laboratories's earnings presentation
Slide 1: Neuland Laboratories Limited Investor Presentation Q4FY26 & FY26
Neuland Laboratories Limited Investor Presentation Q4FY26 & FY26
Slide 2: Safe Harbour
SAFE HARBOUR Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 3: Table of Content
Table of Content Q4FY26 Highlights Company Overview Business Strategy Our Businesses Shareholder Information Q4FY26 Company Business Our Shareholder Annexure Annexure Highlights Overview Strategy Businesses Information 3
Slide 4: Q4FY26 & FY26 Highlights
Q4FY26 & FY26 Highlights 4
Slide 5: Management Commentary
Management Commentary SAHARSH DAVULURI, CEO & MD “We are pleased with the fact that we have ended FY26 on a strong note in line with our original expectations. There is good business visibility in the short to medium term anchored by commercial and near-commercial molecules. Our focus on execution d
Slide 6: Q4 & FY26 Business Overview
Q4 & FY26 Business Overview CMS CMS revenues driven by commercial molecules. Growth in new projects orders which will be delivered over the course of this and next financial years. Traction from Innovators with peptides molecules in pipeline. GDS In Prime segment Ezetimibe and Mirtazapine were the k
Slide 7: Q4FY26 Financial Highlights
Q4FY26 Financial Highlights Total Income EBITDA PAT EPS (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) 40.5% 45.0% 26.9% 30.4% 40.0% 18.7% 35.0% 19.0% 30.0% 212.5 17.3% 25.0% 9.0% 165.6 319.4 788.7 14.4% 8.3% 4.6% 20.0% 516.1 15.0% 96.5 447.8 75.2 156.9 27.7 58.2 42.1 335.8 300.6 10.7 10.0% 31.5 13.7 85.0 21.6 40
Slide 8: FY26 Financial Highlights
FY26 Financial Highlights Total Income EBITDA PAT EPS (Rs. Cr) (Rs. Cr) 29.4% (Rs. Cr) (Rs.) 40.0% 17.7% 17.8% 350.0 550.0 35.0% 17.7% 17.3% 300.0 450.0 22.9% 30.0% 17.6% 2053.1 250.0 283.0 25.0% 363.1 350.0 17.5% 200.0 603.4 1497.3 20.0% 202.2 17.4% 250.0 150.0 342.8 15.0% 17.3% 100.0 259.4 150.0 1
Slide 9: Key Balance Sheet Metrics
Key Balance Sheet Metrics Current Ratio(x) ROCE % Fixed Asset Turnover (x) Debt to Equity (x) 26.1% 3.1 32.8% 2.7 2.6 0.2 2.4 2.3 2.1 2.1 2.1 21.3% 1.7 1.6 17.9% 0.1 0.1 0.1 0.1 9.7% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Particulars (Rs C
Slide 10: Key Operating Metrics Q4FY26
Key Operating Metrics Q4FY26 Top 10 & Top 5 Products Top 10 & Top 5 Customers Top 10 Prime Specialty Top 10 Segment revenue Top 5 CMS Others Top 5 98% 99% 100% 4% 6% 6% 7% 7% 87% 94% 92% 79% 77% 78% 34% 69% 68% 68% 64% 44% 61% 60% 61% 68% 48% 46% 19% 16% 11% 11% 40% 8% 32% 26% 22% 18% Prime Specialt
Slide 11: Key Operating Metrics FY26
Key Operating Metrics FY26 Segment Revenue Prime Specialty Top 10 & Top 5 Products Top 10 Top 10 & Top 5 Customers Top 10 CMS Others Top 5 Top 5 97% 97% 98% 6% 6% 87% 94% 93% 74% 73% 43% 73% 63% 65% 56% 64% 61% 59% 47% 44% 18% 11% 33% 23% FY25 FY26 Prime Specialty CMS Overall Company Prime Specialty
Slide 12: CMS – Revenue Split & Number of Active Projects
CMS – Revenue Split & Number of Active Projects Rs. Cr YoY Movement No. of active CMS projects Q4 FY26 Pre-Clinical P-1 P-2 P-3 Pre-Reg/Reg Commercial Grand Total API 16 13 13 5 3 9 59 1146 Intermediate 4 9 7 5 4 10 39 511 Grand Total 20 22 20 10 7 19 98 126 98 Q4 FY25 Pre-Clinical P-1 P-2 P-3 Pre-R
Slide 13: Company Overview
Company Overview 13
Slide 14: Company Overview
Company Overview Manufacturing of generic Generic APIs non-exclusive APIs Established in Business 1984 verticals Contract development and 40 years in API manufacturing CDMO Services manufacturing of NCE API and development Total reactor volume of 12,26,000 Liters Facilities Inspected by Supported 3
Slide 15: Key Facts
Key Facts 40+ 1007+ 100+ 90% Years of experience DMFs Filed API across 10 diverse Revenue from exports worldwide therapeutic areas 80+ 75 1226 KL 2188 Countries Served Active US DMFs API Manufacturing Employees Capacity 15
Slide 16: Board Of Directors
Board Of Directors Dr. Davuluri D. Sucheth Rao D. Saharsh Rao Mr. Prasad Mr. Homi Rustam Rama Mohan Rao Executive Vice Chief Executive Officer Raghavan Menon Khusrokhan Executive Chairman Chairman & Managing Director Independent Independent Director Director Dr. Ravi Shankar Ms. Pallavi Joshi Mr. Su
Slide 17: Key Milestones
Key Milestones Our Journey 2018 2019 2020 2021 2023 2024 2025 Acquisition of Increased flow of $100 M+ revenue over Unit – III Crossed INR 10 US FDA audit US FDA audit of advanced projects from CMS 75 live CMS projects Commercialization bn revenue. of Unit-I Unit-II intermediates & Japan. US FDA aud
Slide 18: Our Global Presence
Our Global Presence* EUROPE 63% APAC NORTH AMERICA 2% 31% BD office in Princeton, New Jersey Since 2004 JAPAN 1% BD office in Tokyo, Japan Since 2007 LATAM INDIA 1% 1% Headquarters in MENA Hyderabad, India 3 Manufacturing 1% Units Manufacturing and Development partner to customers in over 80 Countri
Slide 19: Manufacturing Facilities Overview
Manufacturing Facilities Overview UNIT - I UNIT - II UNIT - III Bonthapally, Hyderabad 256 kL Pashamylaram, Hyderabad 389 kL Gaddapotharam, Hyderabad 581 kL Year of 1986 1994 2017 Establishment Blocks Block - 1, 2, 3, 4, H, kL & S Block-1, 2, 3, FC, NMSM, Mini plant(A&B) Block - 1, 2, 4, 5, 6, 7 & 8
Slide 20: State-of-the-art R&D Centre
State-of-the-art R&D Centre Infrastructure Significant R&D achievements • 15 Development Labs with space • Several NCE APIs added in NDA or for expansion commercial stage drugs • 70 Fume hoods • Support for multiple APIs each year in • Analytical Labs Phase 2 and Phase 3 clinical candidates • Dedica
Slide 21: Regulatory Filings
Regulatory Filings 75 33 10 17 26 DMFs with Filings with Japanese China DMF Filings with USFDA Health Canada DMF filed filed KFDA Korea 28 289 ~499 30 1007+ Filings with ROW filings EUDMF filings CEPs received Filings till date TGA including across Germany, for different Turkey, Mexico, France, Pola
Slide 22: Financial Highlights FY2017-2026
Financial Highlights FY2017-2026 Rs. Cr FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026 Total Income 588.9 533.7 670.3 766.6 953.0 953.2 1,200.9 1,571.1 1,497.3 2,053.1 EBITDA 106.9 54.6 61.4 105.3 162.5 144.3 281.1 474.5 342.8 603.4 EBITDA Margin 18.1% 10.2% 9.2% 13.7% 17.1% 1
Slide 23: Business Strategy
Business Strategy 23
Slide 24: Neuland Strategy Framework
Neuland Strategy Framework 04 Digitize to enable transparency, compliance, speed of decision making and ease of doing business 01 Invest in new technologies that are valued by our customers and help us differentiate vs. peers 05 Build a world-class talent pipeline and employee value proposition to e
Slide 25: Our Businesses
Our Businesses 25
Slide 26: Generic APIs (GDS)
Generic APIs (GDS) • We are a preferred service provider in the • API manufacturing heritage of over 40 years manufacturing of Active Pharmaceutical Ingredients (APIs) • Flexible 100g to hundreds of tons capacity • Have developed processes for over 100 • Non-competitive advantage (does not APIs with
Slide 27: CDMO Services (CMS)
CDMO Services (CMS) cGMP manufacturing of RSMs/KSMs/Intermediates and APIs for clinical trials and commercial supply Chemistry & manufacturing capabilities Synthetic portion of Carbohydrate Process fermented molecules chemistry optimization IND/NDA filing Deuterated Cyclic and support molecules PEGy
Slide 28: Shareholder Information
Shareholder Information 28
Slide 29: Shareholding Details
Shareholding Details Share Information (as on 31st Mar 2026) NSE Ticker NEULANDLAB Others BSE Ticker 524558 31% Market Cap (Rs. Cr) 15,412.09 Promoters 33% % free-float 67.37% Free-float market cap (Rs. Cr) 10,383 Shares Outstanding 1,28,29,889 FII 3M Average Daily Traded Volume (ADTV) 20% (Shares)*
Slide 30: Annexure
Annexure 30
Slide 31: Profit & Loss Snapshot (Standalone)
Profit & Loss Snapshot (Standalone) Particulars (Rs Cr) Q4FY26 Q4FY25 YoY (%) Q3FY26 QoQ (%) Total Income 788.7 335.8 134.9% 447.8 76.1% EBITDA 319.4 58.2 448.6% 85.0 275.8% EBITDA Margin 40.5% 17.3% 2316 bps 19.0% 2151 bps Exceptional Item* - - - - - Profit Before Tax* 287.0 39.0 636.6% 54.3 428.9%
Slide 32: Revenue & PBT trend
Revenue & PBT trend Rs Cr Revenue 789 516 415 421 444 448 365 395 390 402 315 336 301 257 294 270 222 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q4FY26 PBT* 287 121 130 128 129 110 104 84 92 53 49 54 39 39 24 13 17 Q4FY22 Q1FY23 Q2
Slide 33: Vision and Values
We are creating a healthier world through sustainable practices, trusted partnerships, and agile collaboration Vision and Values (— Innovation Innovative in everything we do (% Transparency Transparent and open in our communication (a Accountability Accountable for our delivery g Empathy Empathy in
Slide 34: Global peptide API market is poised to reach $14Bn by 2030
Global peptide API market is poised to reach $14Bn by 2030. Global peptide therapeutic /API market in $Bn Key market drivers Peptide therapeutic 125 167 Peptide API market to scale by ~$14 Market bn by 2030 driven mainly by rich peptide pipeline and increasing demand for GLP-1. Peptide API $14 marke
Slide 35: Sustainability Framework: ESG commitment & Goals (1/2)
Sustainability Framework: ESG commitment & Goals (1/2) Dimension Focus area Our commitments Key ESG goals (included in Balance Scorecard) Emissions and Reduce both direct (Scope 1 & 2) ❑ FY 2033-34: 58.8%* reduction in Scope 1 & 2 emissions (FY 2023-24 baseline) climate change and indirect (Scope 3)
Slide 36: Sustainability Framework: ESG commitment & Goals (2/2)
Sustainability Framework: ESG commitment & Goals (2/2) Dimension Focus area Our commitments Key ESG goals (included in Balance Scorecard) Diversity and Promote equal opportunity and ❑ FY 2029-30: 10% women in management inclusion build a more inclusive workplace ❑ FY 2029-30: 16% of all hirings will
Slide 37: Glossary
Glossary Term Description Term Description Any substance that is intended for incorporation into a finished drug Drugs (small or large molecule) under development by a Pipeline drugs Active Pharmaceutical product and is intended to furnish pharmacological activity or other manufacturer Ingredient (A
Slide 38: Thank you
Thank you For further information contact IR Desk Neuland Labs Contact: +91 40 6761 1600 Email: ir@Neulandlabs.com Ravi Udeshi / Minakshi Machutre EY IR Contact: +91 22 6192 2000 Email: Ravi.udeshi@in.ey.com / Minakshi.Machutre@in.ey.com